Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1969
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer ; volume:36 ; number:10 ; day:18 ; month:7 ; year:2019 ; pages:927-938 ; date:10.2019
Drugs & aging ; 36, Heft 10 (18.7.2019), 927-938, 10.2019
- Creator
-
van Holstein, Yara
Kapiteijn, Ellen
Bastiaannet, Esther
Bos, Frederiek van den
Portielje, Johanneke
Glas, Nienke A. de
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40266-019-00697-2
- URN
-
urn:nbn:de:101:1-2020020411110686523032
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:03 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- van Holstein, Yara
- Kapiteijn, Ellen
- Bastiaannet, Esther
- Bos, Frederiek van den
- Portielje, Johanneke
- Glas, Nienke A. de
- SpringerLink (Online service)
Other Objects (12)
Blood based immune biomarkers associated with clinical frailty scale in older patients with melanoma receiving checkpoint inhibitor immunotherapy
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Peripheral nervous system adverse events associated with immune checkpoint inhibitors
Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors
Ocular adverse events associated with immune checkpoint inhibitors, a scoping review
Cancer immunotherapy beyond immune checkpoint inhibitors
Antibody‐Conjugated Nanogel with Two Immune Checkpoint Inhibitors for Enhanced Cancer Immunotherapy
Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors—is it time for a paradigm shift?
A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors
Neurologic adverse events of cancer immunotherapy
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Blood based immune biomarkers associated with clinical frailty scale in older patients with melanoma receiving checkpoint inhibitor immunotherapy
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Peripheral nervous system adverse events associated with immune checkpoint inhibitors
Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors
Ocular adverse events associated with immune checkpoint inhibitors, a scoping review
Cancer immunotherapy beyond immune checkpoint inhibitors
Antibody‐Conjugated Nanogel with Two Immune Checkpoint Inhibitors for Enhanced Cancer Immunotherapy
Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors—is it time for a paradigm shift?
A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors
Neurologic adverse events of cancer immunotherapy
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Blood based immune biomarkers associated with clinical frailty scale in older patients with melanoma receiving checkpoint inhibitor immunotherapy
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Peripheral nervous system adverse events associated with immune checkpoint inhibitors
Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors
Ocular adverse events associated with immune checkpoint inhibitors, a scoping review
Cancer immunotherapy beyond immune checkpoint inhibitors
Antibody‐Conjugated Nanogel with Two Immune Checkpoint Inhibitors for Enhanced Cancer Immunotherapy
Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors—is it time for a paradigm shift?
A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors
Neurologic adverse events of cancer immunotherapy